Evolving Payer Coverage Policies on Genomic Sequencing Tests
- 19 June 2018
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (23), 2379-2380
- https://doi.org/10.1001/jama.2018.4863
Abstract
Reimbursement has been cited as a key barrier to the adoption of precision medicine into clinical care.1 This issue has recently attracted attention with the March 2018 Centers for Medicare & Medicaid Services (CMS) national coverage determination on next-generation sequencing tests for patients with advanced cancer.2This publication has 6 references indexed in Scilit:
- Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectivenessClinical Genetics, 2018
- Payer coverage policies for multigene testsNature Biotechnology, 2017
- Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine InitiativeJournal of the National Comprehensive Cancer Network, 2017
- No Solid Evidence, Only Hollow Argument for Universal Tumor SequencingJAMA Oncology, 2016
- Universal Genomic Testing Needed to Win the War Against CancerJAMA Oncology, 2016
- Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data ImplicationsHealth Affairs, 2014